Unicycive Therapeutics appoints veteran drug developer Sara Kenkare-Mitra to board

Unicycive Therapeutics, Inc.

Appointed Sara Kenkare-Mitra, PhD as independent director effective September 6, 2023.
Dr. Kenkare-Mitra is President & Head of R&D at Alector; previously 23 years at Genentech as SVP.
She played key role in >100 IND/CTA filings and 11 drug approvals across multiple diseases.
Her expertise expected to help advance oxylanthanum carbonate toward NDA filing and UNI-494 IND.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sara Kenkare-Mitra

Independent Director

UNCY · Unicycive Therapeutics, Inc.

Effective: 2023-09-05
Filed: September 6, 2023, 7:59 PM ET

On September 5, 2023, Unicycive Therapeutics, Inc. (the “Company”) appointed Sara Kenkare-Mitra as an independent director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sara Kenkare-Mitra was appointed as Independent Director at Unicycive Therapeutics, Inc..

Action: appointed
Role: Independent Director

Exact text from the filing

On September 5, 2023, Unicycive Therapeutics, Inc. (the “Company”) appointed Sara Kenkare-Mitra as an independent director.

View on SEC.gov

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-074164

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.